Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul George Mathew, M.D.

Profile Picture

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Mathew PG, Cooper W. The Diagnosis and Management of Posttraumatic Headache with Associated Painful Cranial Neuralgias: a Review and Case Series. Curr Pain Headache Rep. 2021 Jun 23; 25(8):54. PMID: 34160700.
    Citations:    Fields:    Translation:Humans
  2. Naor MS, Mathew PG, Sharon R. Transient Horner syndrome associated with COVID-19: A case report. eNeurologicalSci. 2021 Dec; 25:100349. PMID: 34151034.
  3. Mathew PG, Najib U, Khaled S, Krel R. Prevalence of Occipital Neuralgia at a Community Hospital-based Headache Clinic. Neurol Clin Pract. 2021 Feb; 11(1):6-12. PMID: 33968466.
    Citations: 1     
  4. Mathew PG, Krivitski D, Sharon R. Erenumab-Induced Severe Nausea Leading to Smoking Cessation: A Retrospective Case Series. Headache. 2020 Nov; 60(10):2563-2569. PMID: 33202039.
    Citations:    Fields:    Translation:Humans
  5. Silberstein SD, Yuan H, Najib U, Ailani J, Morais AL, Mathew PG, Liebler E, Tassorelli C, Diener HC. Non-invasive vagus nerve stimulation for primary headache: A clinical update. Cephalalgia. 2020 10; 40(12):1370-1384. PMID: 32718243.
    Citations: 4     Fields:    Translation:HumansAnimals
  6. Pavlova MK, Latreille V, Puri N, Johnsen J, Batool-Anwar S, Javaheri S, Mathew PG. Novel non-pharmacological insomnia treatment - a pilot study. Nat Sci Sleep. 2019; 11:189-195. PMID: 31572034.
    Citations: 1     
  7. Duvall JR, Mathew PG, Robertson CE. Headache Attributed to Autonomic Dysreflexia: Clinical Presentation, Pathophysiology, and Treatment. Curr Pain Headache Rep. 2019 Aug 27; 23(11):80. PMID: 31456068.
    Citations:    Fields:    Translation:Humans
  8. Mathew PG, Klein BC. Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk. Headache. 2019 09; 59(8):1421-1426. PMID: 31318457.
    Citations: 6     Fields:    Translation:Humans
  9. Mathew PG. Reinforcing Competence without Increasing Physician Burnout: A Maintenance of Certification (MOC) Alternative Study. MD Advis. 2018; 11(1):33-35. PMID: 31498981.
    Citations:    Fields:    
  10. Mathew PG, Robertson CE. No Laughing Matter: Gelastic Migraine and Other Unusual Headache Syndromes. Curr Pain Headache Rep. 2016 May; 20(5):32. PMID: 27038971.
    Citations:    Fields:    Translation:Humans
  11. Mathew PG, Krel R, Buddhdev B, Ansari H, Joshi SG, Spinner WD, Klein BC. A retrospective analysis of triptan and dhe use for basilar and hemiplegic migraine. Headache. 2016 May; 56(5):841-848. PMID: 27062528.
    Citations: 7     Fields:    
  12. Einstein DJ, Ladin K, Mathew P. The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life. JAMA Oncol. 2016 Apr; 2(4):429-30. PMID: 26914544.
    Citations: 3     Fields:    Translation:Humans
  13. Mathew PG. Board Recertification: Should UCNS Continue to Endorse the Highly Scrutinized ABPN/AMBS MOC Programs? Headache. 2016 Apr; 56(4):773-5. PMID: 27092534.
    Citations:    Fields:    Translation:Humans
  14. Mathew PG, Cutrer FM, Garza I. A touchy subject: an assessment of cutaneous allodynia in a chronic migraine population. J Pain Res. 2016; 9:101-4. PMID: 26955290.
    Citations: 3     
  15. Sharon R, Rayhill M, Viknevich J, Charleston L, Mathew PG. An Analysis of UCNS Certified Headache Center Patient Intake Forms. Headache. 2016 Mar; 56(3):519-27. PMID: 26875592.
    Citations: 1     Fields:    Translation:Humans
  16. Mathew PG, Robbins L. Cranial neuralgia vs entrapment neuropathy decompression … better names than migraine trigger site deactivation surgery. Headache. 2015 May; 55(5):706-10. PMID: 25882274.
    Citations: 1     Fields:    Translation:Humans
  17. Mathew PG, Cutrer FM. Injecting under pressure: the pain of low CSF pressure headache responsive to botulinum toxin injections. Curr Neurol Neurosci Rep. 2014 Sep; 14(9):477. PMID: 25027263.
    Citations:    Fields:    Translation:Humans
  18. Mathew PG. A critical re-evaluation of migraine trigger site decompression surgery. Headache. 2014 Jul-Aug; 54(7):1231-3. PMID: 25040812.
    Citations: 2     Fields:    Translation:Humans
  19. Mathew PG, Boes CJ, Garza I. A tale of two systems: cardiac cephalalgia vs migrainous thoracalgia. Headache. 2015 Feb; 55(2):310-2. PMID: 24801614.
    Citations: 2     Fields:    Translation:Humans
  20. Sheikh HU, Mathew PG. Reversible cerebral vasoconstriction syndrome: updates and new perspectives. Curr Pain Headache Rep. 2014 May; 18(5):414. PMID: 24658747.
    Citations: 11     Fields:    Translation:Humans
  21. Mathew PG, Pavlovic JM, Lettich A, Wells RE, Robertson CE, Mullin K, Charleston Iv L, Dodick DW, Schwedt TJ. Education and decision making at the time of triptan prescribing: patient expectations vs actual practice. Headache. 2014 Apr; 54(4):698-708. PMID: 24512184.
    Citations: 3     Fields:    Translation:Humans
  22. Joshi SG, Mathew PG, Markley HG. New daily persistent headache and potential new therapeutic agents. Curr Neurol Neurosci Rep. 2014 Feb; 14(2):425. PMID: 24402404.
    Citations: 4     Fields:    Translation:HumansAnimals
  23. Mathew PG. A critical evaluation of migraine trigger site deactivation surgery. Headache. 2014 Jan; 54(1):142-52. PMID: 24116941.
    Citations: 10     Fields:    Translation:Humans
  24. Wells RE, Markowitz SY, Baron EP, Hentz JG, Kalidas K, Mathew PG, Halker R, Dodick DW, Schwedt TJ. Identifying the factors underlying discontinuation of triptans. Headache. 2014 Feb; 54(2):278-89. PMID: 24001117.
    Citations: 19     Fields:    Translation:Humans
  25. Mathew PG, Dun EC, Luo JJ. A cyclic pain: the pathophysiology and treatment of menstrual migraine. Obstet Gynecol Surv. 2013 Feb; 68(2):130-40. PMID: 23417219.
    Citations: 12     Fields:    Translation:Humans
  26. Mathew PG, Mathew T. Taking care of the challenging tension headache patient. Curr Pain Headache Rep. 2011 Dec; 15(6):444-50. PMID: 21845469.
    Citations: 3     Fields:    Translation:Humans
  27. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012 Jan 01; 118(1):63-71. PMID: 21976132.
    Citations: 67     Fields:    Translation:HumansCTClinical Trials
  28. Mathew PG, Garza I. Headache. Semin Neurol. 2011 Feb; 31(1):5-17. PMID: 21321829.
    Citations: 2     Fields:    Translation:Humans
  29. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol. 2011 Oct; 68(4):889-96. PMID: 21290244.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  30. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2011 Dec; 29(6):1432-40. PMID: 20336348.
    Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
  31. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105. PMID: 19887483.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  32. Vinson J, Mathew P, Beer TM, Carducci MA, Oh W, Small E, Wilding G, Higano C, Hussain M, Scher HI. Prostate cancer clinical trials consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials. J Clin Oncol. 2009 May 20; 27(15_suppl):e16065. PMID: 27963069.
  33. Small E, Harzstark A, Weinberg VK, Smith DC, Mathew P, Beer T, Liu G, Sharib J, Rosenberg J. Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: A phase II study of the DOD Prostate Cancer Clinical Trials Consortium. J Clin Oncol. 2009 May 20; 27(15_suppl):5058. PMID: 27962970.
  34. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 Jul 10; 27(20):3319-24. PMID: 19414670.
    Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
  35. Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol. 2009 Jun 10; 27(17):2772-8. PMID: 19349545.
    Citations: 10     Fields:    Translation:Humans
  36. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan; 7(1):51-7. PMID: 19213669.
    Citations: 9     Fields:    Translation:Humans
  37. Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol. 2009 Jan; 181(1):81-7; discussion 87. PMID: 19012911.
    Citations: 13     Fields:    Translation:Humans
  38. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008 Sep; 180(3):867-72; discussion 872. PMID: 18635226.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  39. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36. PMID: 18559590.
    Citations: 9     Fields:    Translation:Humans
  40. Taplin M, Ko Y, Regan MM, Beer TM, Carducci MA, Mathew P, Bubley G, Oh WK, Kantoff PW, Balk SP. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5068. PMID: 27948754.
  41. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 01; 13(19):5816-24. PMID: 17908974.
    Citations: 46     Fields:    Translation:Humans
  42. Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. J Urol. 2007 Sep; 178(3 Pt 2):S5-8; quiz S4. PMID: 17644118.
    Citations:    Fields:    Translation:Humans
  43. Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer. 2006 Sep; 5(2):144-9. PMID: 17026803.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  44. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer. 2006 Aug 01; 107(3):497-505. PMID: 16795067.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  45. Mathew P, Thall PF, Johnson MM, Oh WK, Meluch AA, Morris MJ, Troncoso P, Bucana CD, Fidler IJ, Logothetis CJ. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4562. PMID: 27952021.
  46. Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer. 2006 May 15; 106(10):2143-7. PMID: 16598751.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  47. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol. 2004 Aug 15; 22(16):3323-9. PMID: 15310776.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  48. Mathew P, Fidler IJ, Logothetis CJ. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol. 2004 Apr; 31(2 Suppl 6):24-9. PMID: 15176001.
    Citations: 6     Fields:    Translation:HumansAnimals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mathew's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (175)
Co-Authors (13)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.